Scholarlink

Background <p><i>Mycoplasma pneumoniae</i> is a common cause of respiratory infections, and the emergence of antibiotic resistance underscores the need for an effective vaccine. This study employed an in silico approach to design a multi-epitope vaccine using genomic data from <i>M. pneumoniae</i>.</p> Methods <p>Candidate antigens were screened based on antigenicity, allergenicity, and toxicity. A non-allergenic, non-toxic antigen was selected to design a construct comprising B-cell and T-cell epitopes, fused with the cholera toxin B subunit as an adjuvant and connected via immunologically favorable linkers. The construct was evaluated through molecular docking, molecular dynamics simulations, binding free energy calculations (MM/GBSA), immune simulation, codon optimization, and in silico cloning.</p> Results <p>The vaccine showed strong binding to TLR4 with a predicted binding energy of − 21.7&#xa0;kcal/mol. Structural validation yielded a ProSA Z-score of − 5.71, an ERRAT score of 84.188%, and 98.7% of residues in favored or allowed regions of the Ramachandran plot. Immune simulations indicated elevated IFN-γ and antibody levels, and population coverage analysis showed global HLA representation of 50.69%.</p> Conclusions <p>The final vaccine construct demonstrated structural stability, strong immune receptor interactions, and broad population coverage in silico, supporting its potential efficacy against <i>M. pneumoniae</i> and warranting further experimental validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An immunoinformatics-based designed multi-epitope candidate vaccine against Mycoplasma pneumoniae

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Behzad Shahbazi,
  • Negar Mottaghi-Dastjerdi,
  • Mohammad Soltany-Rezaee-Rad,
  • Khadijeh Ahmadi

摘要

Background

Mycoplasma pneumoniae is a common cause of respiratory infections, and the emergence of antibiotic resistance underscores the need for an effective vaccine. This study employed an in silico approach to design a multi-epitope vaccine using genomic data from M. pneumoniae.

Methods

Candidate antigens were screened based on antigenicity, allergenicity, and toxicity. A non-allergenic, non-toxic antigen was selected to design a construct comprising B-cell and T-cell epitopes, fused with the cholera toxin B subunit as an adjuvant and connected via immunologically favorable linkers. The construct was evaluated through molecular docking, molecular dynamics simulations, binding free energy calculations (MM/GBSA), immune simulation, codon optimization, and in silico cloning.

Results

The vaccine showed strong binding to TLR4 with a predicted binding energy of − 21.7 kcal/mol. Structural validation yielded a ProSA Z-score of − 5.71, an ERRAT score of 84.188%, and 98.7% of residues in favored or allowed regions of the Ramachandran plot. Immune simulations indicated elevated IFN-γ and antibody levels, and population coverage analysis showed global HLA representation of 50.69%.

Conclusions

The final vaccine construct demonstrated structural stability, strong immune receptor interactions, and broad population coverage in silico, supporting its potential efficacy against M. pneumoniae and warranting further experimental validation.